Award
NIH Reporter #5U19CA264504-05
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
Recipient
Brigham and Women's Hospital, Boston, MA
Award Amount
$191,298.00
Ceiling
$191,298.00
Awarded
September 04, 2025
Identifier
5U19CA264504-05
NIH grant awarded to support clinical trial research on targeted therapies for IDH-mutant grade 4 gliomas, focusing on metabolic vulnerabilities and drug safety evaluation.
Description
A NIH grant for conducting a phase 0 surgical window clinical trial of a brain-penetrant nucleotide metabolism inhibitor in IDH-mutant grade 4 glioma patients, characterizing pharmacokinetics, molecular and cellular effects, and safety.